Roche Committed to innovation and profitable growth. FY 2010 results, February 2, 2011 London, New York

Roche Committed to innovation and profitable growth FY 2010 results, February 2, 2011 London, New York 2

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected 3

Group Severin Schwan Chief Executive Officer 4

2010 Summary Financial guidance fully met Operational Excellence on track Most of the concerned employees individually notified R&D prioritised Divestitures of factories initiated Major progress in Personalised Healthcare Strong late-stage pipeline of 12 NMEs out of which 6 tailored to specific patient groups 5

2010: Group sales Solid underlying growth in line with guidance 2009 2010 change in % Excluding CHF m CHF m CHF local Tamiflu* Pharmaceuticals Division 38,996 37,058-5 -2 +5 Diagnostics Division 10,055 10,415 +4 +8 +8 Roche Group 49,051 47,473-3 0 +5 * local currency 6

2010: Solid growth despite major headwinds CHF bn 3.5 3 2.5 2 1.5 1 0.5 0 Tamiflu sales 2009-2010 2009 2010 Avastin in breast cancer US sales 2009-2010 CHF m 1000 900 800 700 600 500 2009 2010 Healthcare reforms impact* 2009-2010 CHF m 0-100 -200-300 -400-500 -600-700 -800 2009 2010-2.3 bn -125 m -774 m * EU, US and Japan 7

Growth rates maintained despite healthcare reforms and austerity measures 2009 vs. 2008 2010 vs. 2009 Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Pharmaceuticals Division 8 14 15 8 11 10-2 -5-8 -2 excl. Tamiflu 7 7 5-3 4 8 3 4 4 5 Diagnostics Division 8 7 10 10 9 9 9 7 6 8 Roche Group 8 12 14 8 10 9 0-3 -5 0 excl. Tamiflu 7 7 6 0 5 9 4 5 4 5 8

2010: Group performance +10% Core EPS growth 1 as guided Change CHF m 2009 2010 CHF m % loc % Sales 49,051 47,473-1,578-3 0 Core operating profit 16,272 16,591 +319 +2 +7 as % of sales 33.2 34.9 Core net income 11,317 11,181-136 -1 as % of sales 23.1 23.6 Attributable to Roche shareholders 10,636 10,955 +319 +3 Core EPS (CHF) 12.34 12.78 +0.44 +4 +10 1 at constant exchange rates 9

Continuous profit growth and margin improvement Group Core operating profit and margin +2.1%p 1 (+1.7%p) 34.9% % of sales 33.2% 16.3 +7% 1 (+2%) 16.6 CHF bn 2009 2010 1 at constant exchange rates 10

2010: Continuous increase of pay-out ratio over three years 1 CHF 8.00 7.00 6.00 5.00 4.00 3.00 2.00 1.00 0.00 2.00 2.50 Average yearly dividend growth (2004-2010): 22% 3.40 4.60 5.00 6.00 55.0% 51.6% 6.60 2004 2005 2006 2007 2008 2009 2010 Payout ratio 55% 50% 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% 1 As announced in relation to the financial results for 2007 Pay-out ratio calculated as dividend per share divided 2010 Dividend: Proposed by the Board of Directors by core earnings per share (diluted) 1 Pay-out ratio calculated as dividend per share divided compound annual growth rate by earnings (before exceptional items) per share (diluted) 11

2010: Goals achieved Sales growth (in LC) Group & Pharma (excl. Tamiflu): mid single-digit Diagnostics: significantly above market 5% 8% Synergies 2010: CHF 800 m 2011: CHF 1,000 m R&D investment Core EPS growth (in LC) Slightly below 2009 level Double-digit 10% Debt 2010: 33% reduction (revised from 25%) 2015: Aim to return to net cash position 3 yr Dividend outlook Maintained (as announced in 2008)* * Continuous increase in dividend pay-out ratio over the period 2008-2010 12

Priorities 2011 Improve Efficiency Implement Operational Excellence as announced Capture remaining synergies from Genentech integration Drive Innovation and Growth Progress late-stage pipeline Prepare launches for potentially three NMEs (BRAF inhibitor, pertuzumab, hedgehog inhibitor) Launch key diagnostic tests (HPV, BRAF, KRAS, EGFR) 2011: Bring personalised healthcare to patients 13

A leading pipeline 12 NMEs in late-stage development Number of NMEs Virology CNS Metabolic Inflammation Oncology 10 Glycine reuptake inh aleglitazar taspoglutide dalcetrapib 12 HCV pol inh 1 ocrelizumab MS Glycine reuptake inh aleglitazar dalcetrapib lebrikizumab 1 4 ocrelizumab Hedgehog inh MetMAb 1 Hedgehog inh 2 taspoglutide dalcetrapib BRAF inhibitor T-DM1 BRAF inhibitor T-DM1 ocrelizumab Actemra ocrelizumab pertuzumab GA101 (CLL) pertuzumab GA101 (CLL, NHL) pertuzumab 2007 2008 2009 2010 1 LIP decision made, phase III start pending 14

Outlook 2011 Operational Excellence to offset potential adverse factors 2011 2010 Operating profit Top-line pressures & risks EU & US healthcare reforms (CHF ~500 m impact) Lower Tamiflu sales (by CHF ~600 m) Avastin mbc sales at risk (up to CHF ~800 m) Boniva, CellCept patent expiries (up to CHF ~500 m) Positive impact from Organic growth Operational Excellence (CHF 1.8 bn) Genentech synergies (CHF 200 m) Avastin sales in other indications/regions (up to CHF ~500 m) 15

Outlook for 2011 Sales growth (in LC) Genentech synergies Operational Excellence savings Core EPS growth target (in LC) Group & Pharma (excl. Tamiflu): low single-digit Diagnostics: significantly above market 2011+ : CHF 1.0 bn* 2011 : CHF 1.8 bn 2012+ : CHF 2.4 bn High single-digit Debt Aim to return to net cash position by 2015 Dividend outlook Grow dividend in-line with Core EPS growth Barring unforeseen events; LC=Local Currency; * vs. 2010: CHF 0.8 bn 16

Pharmaceuticals Division Pascal Soriot COO Roche Pharmaceuticals 17

2010: Pharma sales - growth maintained despite healthcare reforms and austerity measures 2009 2010 change in % Excluding CHF m CHF m CHF local Tamiflu* Pharmaceuticals Division 38,996 37,058-5 -2 +5 United States 14,805 14,071-5 -1 +4 Western Europe 10,827 9,467-13 -5 +2 Japan 4,765 4,319-9 -12 +3 International 8,599 9,201 +7 +8 +11 Quarterly growth rates % in LC vs. prior year 2009 2010 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Pharmaceuticals Division 8 14 15 8 10-2 -5-8 excl. Tamiflu 7 7 5-3 8 3 4 4 * local currency 18

2010: Impact of Tamiflu and healthcare reforms Strong underlying growth of 7%* from our portfolio CHF m 38,996 ~ CHF 3 bn 37,058 Tamiflu 3,200-2,327 +7% * (+3%) -774 +1,163 Tamiflu 873 35,796 Tamiflu 873 35,022 36,185 2009 Tamiflu HC reforms and Japan price cut 2010 Portfolio growth 2010 * local currency 19

Pharma: Oncology, Lucentis and Actemra driving growth, strong performance in emerging markets Avastin MabThera / Rituxan Herceptin Lucentis Actemra / RoActemra Xeloda Mircera Tarceva Valcyte / Cymevene Kytril Neutrogin NeoRecormon / Epogin CellCept US Western Europe Japan International -400-300 -200-100 0 100 200 300 400 500 600 Tamiflu: CHF -2,342 m Absolute amounts in CHF m at 2009 exchange rates; products with growth contribution CHF +/- 50 m; 20

2010: Pharma - further productivity improvements Costs controlled on all lines 2010 CHF m % sales Sales 37,058 100.0 2010 vs. 2009 local growth -2% Royalties & other op inc 1,537 4.2 Cost of sales -7,947-21.4 M & D -6,652-18.0 R & D -8,160-22.0 G & A -1,060-2.9-18% -12% -14% -1% -2% COGS & PC 1 : -6% Administration: -12% Core operating profit 14,776 39.9 4% 0% in CHF 1 Cost of goods sold & period costs 21

2010: Pharma - strong profit margin increase Pharma Core operating profit and margin 38.0% +2.2%p 1 (+1.9%p) 39.9% % of sales +4% 1 (0%) 14.8 14.8 CHF bn 1 at constant exchange rates 2009 2010 22

Oncology sales up 7% in 2010 Major brands CHF bn Avastin MabThera Rituxan Herceptin local growth +9% +9% +7% Japan and Int l: continued strong growth US: mbc impacted by regulatory uncertainty Continued uptake in CLL and strong use in NHL WE: Benefit from uptake in gastric cancer Japan: negative impact of price cuts in April Xeloda +17% Strong growth in key markets: US, Japan, China Tarceva +6% 2010 2009 Growth in Int l region, Japan and US Oncology 2010 sales: 21.3 bn 0 1 2 3 4 5 6 23

Avastin: continued growth Driven by International regions and Japan CHF bn 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0.0 Global sales 2005 2006 2007 2008 2009 2010 Regional sales Local growth + 9% 1 US 0% Japan +51% International +31% Western Europe +7% US (Q4 10 penetration rates) 1st line mcrc and Avastin-eligible mnsclc: stable 1st line mbc: further downward trend from ~50% at Q3 10 to ~35% (± 5%) new patient share due to regulatory and reimbursement uncertainty Top 4 EU (Q3 10 penetration rates) 1st line mcrc: stable at ~45%, 1st line mnsclc: ~15%, 1st line mbc: ~35% Japan Continued good uptake in mcrc and mnsclc 1 local growth 24

Avastin: opportunities and challenges for 2011 Opportunities Grow market share in mcrc and mnsclc Launch in China (mcrc), continue success in Japan Roll-out of treatment duration program (treatment to progression) Ovarian cancer filings (EU: Dec 2010; US: 2011) Challenges Potential regulatory actions on Avastin mbc label Estimated peak sales: ~ CHF 7 bn 25

Lucentis New indications fueling growth, mitigating risk CHF m 1600 1200 800 400 US sales +27% 1 Growth opportunities AMD: Increase in new patients (~2% per year) and # of injections per patient (currently average of 8 injections in 1 st year and 5 in 2 nd year) Target US population ~215,000 patients RVO: FDA approval in Q2 2010; initial uptake encouraging Target US population ~95,000 patients DME: Phase III data Q1 2011 Target US population ~205,000 patients 0 2008 2009 2010 Lucentis vs. Avastin in eye care CATT Study Expected early 2011 1 in local currency; AMD = wet age-related macular degeneration; RVO = retinal vein occlusion; DME = diabetic macular edema Genentech, a member of the Roche Group, retains commercial rights in the US and Novartis has exclusive commercial rights for the rest of the world 26

Actemra/RoActemra in Rheumatoid Arthritis Successful launch CHF m 140 120 100 80 60 40 20 0 Q1 08 Q2 08 Actemra/RoActemra quarterly sales Q3 08 Q4 08 Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 Q2 10 Q3 10 Q4 10 2010 sales: CHF 397 m Uptake remains very encouraging In US, Actemra prescribed by nearly 60% of rheumatologists, patient share currently 4-6% following anti-tnfs sjia (systemic juvenile idiopathic arthritis): submitted Q4 10, priority review by FDA and EMA FDA label extension: inhibition and slowing of structural joint damage, improvement of physical function (LITHE study) 27

Pharma sales in International region CHF bn 10 9 8 7 6 5 4 3 2 1 0 CAGR: 10% 2006 2007 2008 2009 2010 Tarceva Xeloda CellCept Pegasys Avastin MabThera / Rituxan Herceptin Rest excl. Tamiflu All figures at 2010 exchange rates 28

Herceptin in adjuvant use: 1 year of treatment as the standard of care - potential improvement with 2 years Study FPI Recruitment status Data avail. estimate Additional info HERA (Intl. study) 2001 N=3404 1-year arm=1703 2-years arm=1701 Fully enrolled 2004 2012 24 months vs. 12 months Shorter treatment duration studies FinHer (Finland) Q4 2000 Closed Sept 2003 232 HER2+ patients Published 2009 9 weeks vs. no Herceptin No statistical significance PHARE (France) PERSEPHONE (UK) Greek study (HORG) SOLD (Int. Study) ShortHER (Italy) Q1 2006 3400 Enrollment closed June 2010 Q4 2007 ~1004/ 4000 Q4 2004 ~389/ 450 2012/13 Earliest 2014 Earliest 2013 6 vs. 12 months one sided alpha of 0.05 not registration standard (0.025 required) 6 vs. 12 months 6 vs. 12 months Q1 2008 ~900/ 3000 2014/15 9 weeks vs. 12 months Q4 2007 ~650/ 2500? 9 weeks vs. 12 months Sources: FinHer: JCO, 27(34) 2009; clinicaltrials.gov (CT.gov); PHARE protocole d essai clinique 2009; PERSEPHONE website; primary intelligence and Roche estimates 29

HER2-positive breast cancer Improving the standard of care 2nd line mbc Xeloda + lapatinib T-DM1 (EMILIA) 1st line mbc Herceptin + chemotherapy Herceptin & pertuzumab + chemotherapy (CLEOPATRA) T-DM1& pertuzumab (MARIANNE) Early (adjuvant) BC Herceptin + chemotherapy Herceptin Subcutaneous + chemotherapy Herceptin & pertuzumab + chemotherapy 2010 2011 2012 2013 2014 2015 2016 Timelines refer to the expected dates of first filing 30

Biosimilars in Western Europe - limited impact on value even in markets with regulatory pathway 35% EPO market Value 100% G-CSF market Value 30% 25% 20.70% 80% 94.40% 20% 60% 15% 10% 5% 0% EPO Biosimilars Value share EPO Mircera Value share EPO NeoRecormon Value share 7.00% 4.60% 40% 20% 0% G-CSF Biosimilars Value share G-CSF Branded Value share 5.60% 45% Volume 100% Volume 40% 35% 30% 25% 20% 15% 10% 5% EPO Biosimilars Volume share EPO Mircera Volume share EPO NeoRecormon Volume share 27.40% 10.40% 2.90% 80% 60% 40% 20% G-CSF Biosimilars Volume share G-CSF Branded Volume share 86.60% 13.40% 0% 0% Q4 07 Q1 08 Q2 08 Q3 08 Q4 08 Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 Q2 10 Q3 10 Q4 08 Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 Q2 10 Q3 10 2007 2008 2009 2010 2008 2009 2010 Source: IMS PADDS 31

Opportunities in emerging markets Large untapped potential for our innovative products Opportunities in emerging markets strong and long-standing presence providing access is key: disease awareness, local clinical trials and training for healthcare professionals specific pricing programmes for individual markets: innovative schemes to provide win-win situation Current penetration (%) Herceptin MabThera oncology China 7% 12% Russia 25% 26% Emerging markets: by 2012 ~ 80% of US market value, more than Western Europe (IMS) 32

Growth despite biosimilars HER2 market example 3 New HER2 targeted products 1 Herceptin value assumption post biosimilars launch based on the German EPO market experience Value decline EU and RoW 2 Increased penetration in International markets Pertuzumab T-DM1 Herceptin sub cut. ROW ROW ROW ROW WE WE WE WE US US US US 2010 ~2017 Emerging markets growth New products 33

2011: Major clinical news for late-stage NMEs 7 Phase III and 9 Phase II studies Compound Indication Study BRAF inh 1st line met melanoma Ph III BRIM3 Lucentis diabetic macular edema Ph III RIDE; Ph III RISE Avastin relapsed ovarian cancer Ph III OCEANS Pertuzumab + Herceptin 1st line HER2+ mbc Ph III CLEOPATRA Herceptin adj HER2+BC sc Ph III HANNAH Actemra Early RA Ph III Head-to-head against Humira Hedgehog Pathway Inh advanced BCC Ph II pivotal study T-DM1 1st line HER2+ mbc Ph II PFS data GA101 Relapsed indolent NHL Ph II Head-to-Head against MabThera/Rituxan MetMab NSCLC 2nd / 3rd line Ph II final data Lebrikizumab asthma Ph II MILLY Nucleoside Pol Inh Hepatitis C Ph IIb PROPEL final data; JUMP-C Dalcetrapib Atheroclerosis CV risk red. Ph IIb dal-vessel; dal-plaque 34

RG7204 for metastatic melanoma meets overall survival endpoint in Phase III Patient Population Second- and Third line Malignant Melanoma BRAF mutation positive First-line Malignant Melanoma BRAF mutation positive Phase/Study Phase II BRIM2 Phase III BRIM3 # of Patients N=132 N=675 Design Single ARM: RG7204 ARM A: RG7204 ARM B: dacarbazine Primary Endpoint Status Best overall response rate assessed by IRC using RECIST criteria Overall survival Presented at Int. Melanoma Congress 2010 FPI Q1 2010; fully recruited in Dec 2010 Met OS and PFS endpoints in Jan 2011 Expect filing in 2011 in US and EU 35

Hedgehog pathway inhibitor in basal cell carcinoma Phase I efficacy data RG3616 is efficacious in treating advanced basal cell carcinoma 33 BCC patients treated in Phase I* >50% had a response (IRF assessed) 2 (6.1%) complete response 16 (48.5%) partial response Median duration of response >8.8 months Well-tolerated with reversible, mild adverse events Pivotal phase II data in Q1 2011 In collaboration with Curis * Von Hoff, et al., New England Journal of Medicine, September 2009 36

Herceptin & pertuzumab in neoadjuvant HER2+ BC An encouraging result from NEOSPHERE trial p = 0.0198 50% p = 0.0141 p = 0.003 pathological complete response 45% 40% 35% 30% 25% 20% 15% 10% 5% 29.0% 45.8% 16.8% 24.0% 0% Herceptin + Herceptin & Herceptin & pertuzumab + docetaxel pertuzumab + pertuzumab docetaxel docetaxel Phase III (CLEOPATRA) data in 1 st line patients and filing in 2011 ITT population summary SABCS 2010 37

Priorities in 2011 Focus on long term growth while managing the short term profitability Prepare for potential launch of BRAF inhibitor, pertuzumab, Hedgehog inhibitor Strengthen investment in emerging markets Continue investment in late-stage pipeline Operational Excellence 38

Diagnostics Division Daniel O Day COO Roche Diagnostics 39

2010: Diagnostics Division sales Sustained high growth above the market 2009 2010 CHF local CHF m CHF m growth growth Professional Diagnostics 4,553 4,858 7% 11% Diabetes Care 2,969 2,959 0% 4% Molecular Diagnostics 1,183 1,189 1% 4% Applied Science 870 868 0% 4% Tissue Diagnostics 480 541 13% 17% Diagnostics Division 10,055 10,415 4% 8% IVD market growth estimated 4-5%

2010: Diagnostics Division sales Growth above market in all regions North America 26% Dia sales, +5% EMEA 1 50% Dia sales, +6% Japan 5% Dia sales, +4% Latin America 7% Dia sales, +16% Asia Pacific 12% Dia sales, +20% 1 Europe, Middle East and Africa All growth in local currency IVD market growth estimated 4-5%

2010: Diagnostics profit improvement on track Significant profit and margin increase driven by strong sales and tight management of operating expenses 2010 CHF m % sales Sales 10,415 100.0 2010 vs. 2009 local growth 8% Royalties & other op inc 157 1.5 Cost of sales -4,564-43.8 M & D -2,515-24.1 R & D -890-8.6 G & A -401-3.9 7% 4% 4% -2% -4% COGS & PC 1 : +5% Administration: +5% Core operating profit 2,202 21.1 30% +26% in CHF 1 Cost of goods sold & period costs 42

2010: Diagnostics performance Operating free cash flow increase driven by profit growth 17.3% 1,742 21.1% +3.6%p 1 (+3.8%p) +30% 1 (+26%) 2,202 11.5% 15.7% +4.3%p 1 (+4.2%p) +48% 1 (+42%) % of sales 1,152 1,634 CHF m 1 at constant exchange rates 2009 2010 Core operating profit 2009 2010 Operating free cash flow 43

Accelerated delivery of ongoing initiatives for sustainable margin improvement Ongoing operational efficiency programmes manufacturing excellence (COGs) consolidation of services (regional call centres, shared services) active portfolio management Further streamlining of sites (site closures 2013-2014) Graz Burgdorf Mannheim Blood gas & electrolytes Insulin delivery systems (IDS) R&D IDS manufacturing outsourced Chemical raw material manufacturing Rotkreuz Mannheim Penzberg Enhancing system integration Leveraging existing capacities Reducing infrastructure costs 44

Growth driven by Professional Diagnostics and Diabetes Care CHF bn 2010 vs. 2009 local growth Professional Dia +11% Strong placements of cobas 6000 & 8000 modular analyzers; cobas e 602 module launched; Expanding immunoassay menu Diabetes Care +4% Maltose-independent strip chemistries for Accu-Chek Aviva, Performa, Compact and Mobile commenced roll-out in EU Molecular Dia +4% Strong demand in APAC for virology and cobas 4800 system for CT/NG & HPV; HPV Test under FDA review Applied Science +4% Double-digit increase in sequencing due to GS Junior; Second half impacted by lower demand for H1N1 testing Tissue Dia +17% EMEA North America RoW Growth driven by IHC/ ISH reagents and BenchMark ULTRA; 15 new Abs (IHC) + 6 new probes (ISH) launched 0 1 2 3 4 5 EMEA = Europe, Middle East and Africa, APAC = Asia Pacific 45

Immunoassays driving sales Ten consecutive years of double-digit growth CHF bn 2.0 Immunoassay sales CAGR 13% c 701/c502 e 602 cobas 8000 series (large-vol) 1.5 cobas 6000 (mid-vol) +17% Strong placements of cobas modular platforms consolidating clinical chemistry & immunoassays 1.0 0.5 0.0 2001 2010 Local growth rates to year earlier period Expanding menu HIV combi, HSV-1, HSV-2, Rubella IgM, HAV. HCV free β HCG/ PAPP-A stat NT-proBNP 46

New Accu-Chek products driving above-market 1 growth in Diabetes Care CHF bn 3 Diabetes Care sales +4% 2 New product launches 3 (2008-2009) Accu-Chek Aviva Nano & Performa Nano Small, sleek design developed for young, high-frequency testers 2 1 Accu-Chek Mobile Only strip-free system enabling less steps for greater ease of use 0 2008 2009 2010 Total Diabetes Care sales New product sales* Accu-Chek Combo First interactive insulin pump in EU allowing patients to operate pump by meter 1 BG market growth estimated 2% 2 local currency 3 Not available in the US * New product sales includes: Accu-Chek Aviva/ Nano, Accu-Chek Performa/ Nano, Accu-Chek Mobile, Accu-Chek Combo 47

Creating medical value and improving patient care Three trials demonstrating the value of diagnostics ATHENA PROTECT STeP Diagnostics HPV (cervical cancer) NT-proBNP (heart failure) Glucose monitoring (diabetes) Companion Diagnostics 47,000 women screened by cobas 4800 HPV Test with 16/18 genotyping 1/10 women 1 positive for HPV 16/18 had cervical precancer although their PAP test was normal 2 NT-proBNP levels used to guide heart failure (HF) therapy Patients experienced significant reduction in total cardiovascular events and HF-related hospitalisations 3 Patients created 7-point BG profiles over 3 consecutive days Therapy decisions based on pattern analysis Patients showed significantly better HbA1c and glycemic control 4 1 >30 years old 2 Wright TC, et al, IPV Montreal, July 2010 3 Januzzi, J., AHA Chicago, November 2010 4 Polonsky et al, Diabetes Care, 34, 2011

Creating medical value and improving patient care Six NMEs in late-stage development have PHC approach Diagnostics HER2/3 (Pertuzumab) Met (MetMAb) Periostin (lebrikizumab) Companion Diagnostics HER2 (T-DM1) BRAF V600 (BRAF inh) HCV load, genotype (HCV pol inh) NMEs = new molecular entities PHC = Personalised Healthcare Not all products available in all countries; some products in development 49

Acquisitions, collaborations and licensing of IP to strengthen businesses Acquisitions Research & technology collaborations Intellectual Property Semi-disposable micropump for insulin delivery High resolution, whole-slide scanning of tissue samples & algorithms IBM and DNA electronics (sequencing) German Cancer Research Centre (HPV) InterComponentWare (Diabetes Care) EGFR Pl3K p63

Key launches for 2011* Professional Diagnostics Diabetes Care Molecular Diagnostics Applied Science Tissue Diagnostics Vitamin D total and HE4 immunoassays (EU) cobas 8000 modular analyzer series, cobas c 702 module (EU, US) cobas b 123 POC system for bloodgas & electrolytes (US) Accu-Chek Mobile LCM (EU) Accu-Chek Combo (US) Accu-Chek Nano (US) cobas 4800 HPV Test (US) cobas 4800 EGFR Mutation Test (EU) cobas 4800 KRAS Mutation Test (EU) cobas 4800 BRAF V600 Mutation Test (EU, US) HLA genotyping on GS Junior & FLX sequencing systems (global) GS FLX Titanum-XL system (global) Ultra-high resolution CGH arrays (global) ER/PR antibody for IHC (US) HER2 dual colour ISH probe (US) FutureView detection system (US, EU) Diagnostics Division Outlook: Sales growth significantly above the market * Subject to appropriate regulatory approvals barring unforeseen events 51

Priorities in 2011 Drive above-market growth Deliver key product launches Drive Personalised Healthcare with Pharma Continue strong growth in emerging markets Further improve profitability 52

Group Erich Hunziker Chief Financial Officer 53

2010: Goals achieved Sales growth (in LC) Group & Pharma (excl. Tamiflu): mid single-digit Diagnostics: significantly above market 5% 8% Synergies 2010: CHF 800 m 2011: CHF 1,000 m R&D investment Core EPS growth (in LC) Slightly below 2009 level Double-digit 10% Debt 2010: 33% reduction (revised from 25%) 2015: Aim to return to net cash position 3 yr Dividend outlook Maintained (as announced in 2008)* * Continuous increase in dividend pay-out ratio over the period 2008-2010 54

2010: Group results Stable sales, Core EPS growth at 10% CHF m % change 2009 2010 CHF local Sales 49,051 47,473-3 0 Core operating profit 16,272 16,591 +2 +7 % of sales 33.2 34.9 +1.7 p IFRS operating profit 12,277 13,486 +10 +15 % of sales 25.0 28.4 +3.4 p Operating free cash flow 15,722 14,149-10 -6 % of sales 32.1 29.8-2.3 p Core net financial income -1,668-2,272 +36 Core tax rate in % 22.5 21.9-0.6 p Core net income 11,317 11,181-1 % of sales 23.1 23.6 +0.5 p Core EPS (CHF) 12.34 12.78 +4 +10 Free cash flow 8,893 4,699-47 55

2010: Group core operating performance Further profit and margin increase 2010 CHF m % sales Sales 47,473 100.0 2010 vs. 2009 local growth 0% Royalties & other op inc 1,694 3.6 Cost of sales -12,511-26.4 M & D -9,167-19.3 R & D -9,050-19.1 G & A -1,848-3.9-16% COGS & PC 1 : -1% -7% Administration: -3% -5% -2% 0% Core operating profit 16,591 34.9 7% +2% in CHF 1 Cost of goods sold & period costs 56

Group core operating profit and margin Substantial margin increase in both Divisions 33.2% 34.9% +2.1%p 1 (+1.7%p) 38.0% 39.9% +2.2%p 1 (+1.9%p) % of sales 16'272 +7% 1 (+2%) 16'591 14'836 +4% 1 (0%) 14'776 17.3% 21.1% +3.6%p 1 (+3.8%p) CHF m 2009 2010 1'742 +30% 1 (+26%) 2'202 1 at constant exchange rates Roche Group Pharma Division Diagnostics Division 57

2010: Group operating performance Non-core items Change CHF m 2009 2010 CHF m % loc % Sales 49,051 47,473-1,578-3 0 Core operating profit 16,272 16,591 +319 +2 +7 as % of sales 33.2 34.9 Non-core items -3,995-3,105 +890-22 IFRS Operating profit 12,277 13,486 +1,209 +10 +15 as % of sales 25.0 28.4 Global restructuring Genentech -2,415-596 +1,819-75 Operational Excellence - -919-919 - Intangible Assets Amortisation -712-619 +93-13 Intangible Assets Impairments -382-667 -285 +75 Alliances & business combinations -31-5 +26-84 Legal and environmental -455-299 +156-34 Non-core items -3,995-3,105 +890-22 Total Operational Excellence costs incl. intangible assets impairments - -1,343-1,343-58

2010: Core net financial result Decline driven by early bond redemptions and currency devaluation in Venezuela 0-500 -1'000-1'668-144 call of USD 2.5 bn notes that were due 1 March 2012 (H1) -108 call of USD 1.0 bn notes that were due 1 March 2014 (H2) -2'272 CHF m -1'500-2'000-2'500-246 * -180-154 -116 +92-3'000 Early bond Fx result, Interest Interest All other, Dec 09 redemptions net and debt expense net Dec 10 security income 59 * Includes CHF 9 m in 2009

2010: Group cash flow Strong free cash flow reduces net debt by 20% CHF bn 0-23.9 Taxes -2.8 Treasury -1.4 Dividends -5.3-9.4-19.2 +14.1 0.0 +4.7 Net debt 31/12/09 Operating Free Cash Flow Non-op. FCF Free Cash Flow Currency translation, fair value & other movements Net debt 31/12/10 60

CHF 8.6 bn bond repayments in 2010 33% of Genentech transaction related debt repaid 100% 75% 50% 25% 0% 9 10 11 12 13 14 15 16 17 19 21 39 USD EUR CHF GBP Repayments 2010: USD 3.0 bn and EUR 1.5 bn floating rate notes in Q1 Early redemption of USD 2.5 bn 4.5% notes due 2012 in September (full redemption) USD 0.5 bn Genentech legacy note Of the CHF 48.2 bn bonds and notes issued to finance the Genentech transaction, cumulative 15.7 bn (33%) repaid as of 31 Dec 2010 1 Outlook 2011: USD 0.9 bn floating rate note repayment at maturity in February Early redemption of USD 1.0 bn 5.0% notes due 2014 in March (partial redemption) 1 Original net proceeds in CHF 61

Debt maturity profile CHF bn 9 8 7 6 2.5 bn called 5 4 1 bn on call 3 2 1 0 2009 2010 2011 2012 2013 2014 2015 2016 2017 2019 2021 2023 2035 2039 USD USD GNE EUR GBP CHF Nominal values @ March 09 FX rates 62

5 year Credit Default Swap (CDS) Roche vs. Germany 300 250 200 150 Germany 45 bp Roche 39 bp 100 50 0 01.09.2008 01.03.2009 01.09.2009 01.03.2010 01.09.2010 Germany Roche 63

Balance sheet 31 December 2010 Equity ratio up from 13% to 19% CHF bn 74.6 74.6 Cash and marketable securities Other current assets 18.5 19.9 25% 27% 61.0 10.9 18% 16.7 27% Current liabilities 22.1 29% 61.0 15.0 25% Non-current liabilities 43.1 58% 34.4 56% Non-current assets 36.1 48% 33.4 55% Equity (Net assets) 9.4 13% 11.7 19% 31.12.2009 31.12.2010 31.12.2009 31.12.2010 Assets Equity & liabilities 64

Outlook for 2011 Sales growth (in LC) Genentech synergies Operational Excellence savings Core EPS growth target (in LC) Group & Pharma (excl. Tamiflu): low single-digit Diagnostics: significantly above market 2011+ : CHF 1.0 bn* 2011 : CHF 1.8 bn 2012+ : CHF 2.4 bn High single-digit Debt Aim to return to net cash position by 2015 Dividend outlook Grow dividend in-line with Core EPS growth Barring unforeseen events; LC=Local Currency; * vs. 2010: CHF 0.8 bn 65

66

Roche Group Development Pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group 2010 sales Diagnostics Foreign exchange rate information 67

Roche Group R&D Pipeline today phase I (36 NMEs) phase II (18 NMEs + 8 Als) phase III (8 NMEs + 25 Als) Registration (6 Als) RG3639 RG7256 RG7112 RG7160 RG7167 RG7304 RG7321 RG7334 RG7414 RG7420 RG7421 RG7422 RG7440 RG7444 RG7459 RG7593 RG7594 RG7597 RG7686 CHU CHU RG4934 RG7185 RG7413 RG7432 CHU RG4929 RG7236 RG7273 RG7418 RG7685 RG1578 RG1662 RG7166 RG7412 RG7417 dulanermin cancer BRaf inh(2) BRAF mutated melanoma MDM2 ant (2) solid & hem tumors EGFR Mab solid tumors CIF/MEK inh solid tumors Raf & MEK dual inh solid tumors PI3 kinase inh solid tumors anti-plgf Mab solid tumors anti-egfl7 Mab solid tumors MEK inh solid tumors MEK inh solid tumors PI3 K/mTOR inh solid&hem tumors AKT inhibitor solid tumors FGFR3 Mab multiple myeloma IAP ant (2) solid tumors& lymphoma CD22 Mab ADC hem. malignancies antiangiogenic solid tumors anti-her3 Mab m. epithelial tumors anti-glypican Mab liver cancer ALK inhibitor NSCLC - solid tumors anti-il-17 Mab RA CRTH2 antag asthma Mab Beta7 ulcerative colitis nucleoside pol inh (9) HCV serine palmitoyltransf inh HCV 11 beta HSD inh metabolic diseases Cat S antag CV risk in CKD ABCA1 inducer dyslipidemia anti-oxldl Mab sec prev CV events GIP/GLP-1 dual ago type 2 diabetes mglur2 antag (2) depression GABA-A a5 inv ago cogn. disorders triple reuptake inh depression anti-abeta Mab Alzheimer s anti-factor D Mab geographic atrophy RG1273 pertuzumab HER2+ EBC RG1273 pertuzumab HER2+ mbc 2 nd line RG3502 T-DM1 HER2+ EBC RG3616 hedgehog path inh advanced BBC RG3616 hedgehog path inh operable BCC RG3638 MetMab mnsclc RG7159 GA101 anti-cd 20 Mab NHL & CLL RG7204 BRaf inh met. melanoma 2nd/3rd l.ine RG7433 navitoclax (ABT-263) sol & hem tumors CHU topoisomerase I inh gastric cancer RG3637 1 lebrikizumab (anti-il13) asthma RG4930 OX40L Mab asthma RG7415 rontalizumab (IFN alpha Mab) SLE RG7416 anti-lt alpha Mab RA RG3648 Xolair chronic idiopathic urticaria RG7449 RG3484 RG7128 RG7227 RG1512 RG7201 2 RG1450 RG1594 RG3487 RG7090 EVO anti-m1 prime Mab HPV16 1 LIP transition approved 2 Ph3 in Japan 3 Complete response in the US 4 FPI Feb 2011 cervical neoplasia nucleoside polymerase inh. HCV danoprevir P selectin Mab SGLT2 inh ocrelizumab nic alpha7 (protease inh) HCV type 2 diabetes gantenerumab (A-beta) Alzheimer s Alzheimer s mglur5 antag (2) TRD NMDA receptor antag asthma CVD RRMS TRD RG105 RG105 3 RG435 RG435 RG435 RG435 RG435 RG435 RG435 RG435 RG435 RG435 3 RG597 RG597 RG1273 RG1415 RG1415 RG3502 RG3502 RG7159 RG7159 RG7204 RG1569 RG1569 RG1569 RG1569 RG1439 RG1658 RG1594 4 RG1678 RG1678 RG3645 RG3645 Rituxan MabThera Avastin NHL fast infusion HER2+ BC adj Avastin mbc combo Herceptin 1 st line Avastin Avastin Avastin NSCLC adj HER2- BC adj Avastin relapsed ovarian ca Avastin Avastin Avastin Avastin pertuzumab aleglitazar triple neg BC adj high risk carcinoid glioblastoma 1 st line Herceptin HER2+ BC sub cut. Herceptin Tarceva Tarceva T-DM1 T-DM1 GA101 anti-cd 20 Mab GA101 anti-cd 20 Mab BRaf inh CV risk reduction in T2D dalcetrapib atherosclerosis CV risk red. GRI schizophrenia negative sympt. Lucentis Lucentis NHL sc formulation mcrc TML HER2+ adj BC (2yrs) HER2+ mbc 1 st line NSCLC adj NSCLC EGFR mut 1 st line HER2+ mbc 1 st line HER2+ advanced mbc CLL inhl met. melanoma 1st line Actemra ankylosing spondylitis Actemra sc formulation RA Actemra early RA Actemra RA DMARD IR H2H ocrelizumab GRI mbc 2 nd line PPMS schizophrenia subopt control diabetic macular edema AMD high dose RG435* RG435* RG1415* RG105** RG1569 CHU * in the EU ** in the US Avastin ovarian cancer 1 st line Avastin mbc combo Xeloda 1 s t line Tarceva NSCLC EGFR mut 1 st line Rituxan ANCA assoc vascul Actemra sjia EPOCH chemo induced anemia NME Additional Indication Oncology Inflammation/Immunology Virology Metabolic/Cardiovascular CNS Ophthalmology Others RG-No Roche Genentech managed CHU Chugai managed EVO Evotec RG105 MabThera is branded as Rituxan in US and Japan RG1569 Actemra is branded as RoActemra in EU 68 Status as of December 31, 2010

Changes of the development pipeline since November 10 (last pipeline update) New to Phase I New to Phase II New to Phase III New to Registration Transitioned from Ph0 RG7236 Cat S antag. CV risk reduction in CKD New NME in Ph1 RG7685 GIP/GLP-1 dual agonist in T2D (Marcadia acquisition) RG7686 anti-glypican Mab in HCC (opted in from Chugai) Added by Chugai ALK inhibitor in NSCLC Unnamed molecule solid tumors New NMEs in Ph2 RG7449 anti-m1 prime Mab in asthma RG1512 P-selectin humab in PVD RG1450 gantenerumab in AD New Ph3 trial (1NME) RG1594 ocrelizumab in PPMS New Ph3 trials (2AIs) RG105 MabThera SC in oncology RG1678 GRI in Schizophrenia suboptimally controlled Transitioned from Ph3 (1AI) Avastin ovarian cancer following NDA submission in EU Removed from Phase I Removed from Phase II Removed from Phase III Removed from Reg. Discontinuation (2NMEs) RG7348 nucleoside analogue in HCV RG7347 anti-nrp1 in solid tumors Reverted to Partner (1NME) RG7426 BHT-3021 in T1D Outlicensing candidate RG667 palavarotene in emphysema Returned to Ipsen (1NME) RG1583 taspoglutide in T2D Removed following FDA decision Avastin mbc combo docetaxel Avastin mbc 2nd line (following FDA complete response) Rituxan inhl 1st line maintenance Removed following approval in Japan Edirol osteoporosis 69

Projected NME submissions and their additional indications Projects currently in Phase 2 and 3 GA101 (RG7159) NHL MetMab (RG3638) mnsclc anti-lt alpha Mab (RG7416) rheumatoid arthritis danoprevir (HCV protease inh RG7227) navitoclax ABT-263 (RG7433) solid & hem tumors HPV16 (RG3484) cervical neoplasia T-DM1 (RG3502) HER2+ mbc 1st line aleglitazar CV risk reduction in T2D pertuzumab HER2+EBC SGLT2 inh (RG7201) type 2 diabetes Hedgehog path inh (RG3616) operable basal cell ca P selectin humab (RG1512) CVD GA101 (RG7159) CLL rontalizumab (anti IFN alpha) SLE gantenerumab (RG1450) Alzheimer s disease pertuzumab HER2+ mbc1st line nucleoside polymerase inh (RG7128) HCV OX40L humab (RG4930) asthma mglur5 antag (2) (RG7090) Txt resistant depression BRAF inh (RG7204) met. melanoma dalcetrapib atherosclerosis CV risk red. lebrikizumab (IL-13) asthma alpha7 nic ago (RG3487) Alzheimer s disease Hedgehog inh (RG3616) advanced basal cell ca T-DM1 (RG3502) HER 2+ advanced mbc glycine reuptake inhib. (RG1678) schizophrenia# anti-m1 prime Mab (RG7449) asthma 2011 2012 2013 Post Post 2013 2013 ocrelizumab PPMS and RRMS Unless stated otherwise, submissions are planned to occur in US and EU. # negative symptoms and sub-optimal control. Oncology Inflammation/Immunology Virology Metabolic/Cardiovascular CNS Ophthalmology NME 70 Status as of December 31, 2010

Projected additional indications submissions of existing products Projects currently in Phase 2 and 3 Avastin HER2+ BC adj Avastin mcrc TML Avastin triple negative BC adj Avastin mbc 2 nd line (EU) Herceptin sc formulation HER2+ Avastin glioblastoma 1 st line Rituxan NHL faster infusion (US) Avastin + Herceptin HER2+ mbc 1 st line Herceptin HER 2+ BC adj 2 years Tarceva (EU) NSCLC EGFR mutation 1 st line Avastin ovarian cancer 1 st line (US) MabThera sc formulation (EU) Xolair (US) chronic idiopathic urticaria Avastin ovarian cancer 1 st line (EU) Avastin relapsed ovarian cancer Actemra ankylosing spondylitis Actemra early RA Avastin HER 2- BC adj Actemra sjia Tarceva (US) NSCLC EGFR mutation 1 st line Actemra RA DMARD H2H (EU) Actemra sc formulation (US) Avastin NSCLC adj Rituxan ANCA assoc vasculitis (US) Lucentis diabetic macular edema (US) Actemra sc formulation (EU) Lucentis AMD high dose (US) Tarceva NSCLC adj 2010 2011 2012 2013 Post 2013 Unless stated otherwise, submissions are planned to occur in US and EU. indicates a submission which has occurred with regulatory action pending Registration based on published data. Oncology Inflammation/Immunology Virology Metabolic/Cardiovascular CNS Ophthalmology 71 Status as of December 31, 2010

Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group 2010 sales Diagnostics Foreign exchange rate information 72

Avastin Breast cancer development programme Patient population First-line HER2-negative Second-line HER2-negative First-line HER2-positive Phase/study Phase III RIBBON-1 Phase III AVADO Phase III RIBBON-2 Phase III AVEREL # of patients N=1,238 N=736 N=684 N=410 Design ARM A: Anthracycline or taxane plus Avastin OR Xeloda plus Avastin ARM B: Anthracycline or taxane plus placebo OR Xeloda plus placebo Avastin dose 10 mg/kg q2 weeks or 15 mg/kg q3 wks Primary endpoint Status Progression-free survival (PFS) EMA - CHMP recommends against a label extension with Xeloda FDA - Received Complete Response Letter Q4 2010 ARM A: Placebo plus docetaxel ARM B: 7.5 mg/kg dose of Avastin plus docetaxel ARM C: 15 mg/kg dose of Avastin plus docetaxel 15 mg/kg or 7.5 mg/kg q3 weeks ARM A: Chemotherapy (taxane, Xeloda, gemcitabine, or vinorelbine) plus Avastin ARM B: Chemotherapy plus placebo 15 mg/kg q3 weeks ARM A: Docetaxel plus Herceptin ARM B: Docetaxel plus Herceptin plus Avastin 15 mg/kg q3 weeks Progression-free survival Progression-free survival Progression-free survival EMA - CHMP recommends removal of the combination of Avastin plus docetaxel from the label FDA - Received Complete Response Letter Q4 2010 EMA - submission gated on RIBBON-1 procedure completion FDA - Received Complete Response Letter Q4 2010 FPI Q3 2006 Enrolment completed Q1 2010 Expect data 2011 The EMA has confirmed that Avastin in combination with paclitaxel has been convincingly shown to enable women with metastatic breast cancer to live longer without their disease getting worse (PFS). Paclitaxel is the chemotherapy most frequently used in Europe and also most frequently partnered with Avastin for the first-line treatment of metastatic breast cancer. Genentech has submitted a request for an FDA hearing and has submitted its response to the FDA's Notice of Opportunity for a Hearing ("NOOH") on the Agency's proposal to withdraw approval of the metastatic breast cancer indication for Avastin in the United States. 73

Avastin Ovarian cancer clinical development programme Patient population Phase/study Phase III GOG-0218 Front-line metastatic ovarian cancer Phase III ICON7 Relapsed platinum-sensitive ovarian cancer Phase III OCEANS # of patients N=1,873 N=1,528 N=484 Design ARM A: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent placebo followed by placebo alone for up to 22 cycles (15 months) ARM B: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by placebo alone for up to 22 cycles (15 months) ARM C: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by Avastin alone for up to 22 cycles (15 months) ARM A: Paclitaxel and carboplatin for 6 cycles ARM B: Paclitaxel and carboplatin plus concurrent Avastin for 6 cycles followed by Avastin alone for up to 18 cycles (12 months) ARM A: Carboplatin, gemcitabine, and concurrent placebo for 6 cycles, followed by placebo alone until disease progression ARM B: Carboplatin, gemcitabine, and concurrent Avastin for 6 cycles, followed by Avastin alone until disease progression. Avastin dose 15 mg/kg q3 weeks 7.5 mg/kg q3 weeks 15 mg/kg q3 weeks Primary endpoint Status Progression-free survival Progression-free survival Progression-free survival Study met its primary endpoint with prolonged administration of Avastin (ARM C) Q1 2010 Data presented at ASCO 2010 EMA submission Q4 2010 Expect FDA submission 2011 Study met its primary endpoint Q3 2010 Data presented at ESMO 2010 ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical Oncology. Enrolment completed Q1 2010 Expect data 2011 74

Avastin Clinical development programmes in other tumor types Patient population Metastatic colorectal cancer High risk carcinoid Newly diagnosed glioblastoma Phase/study Phase III ML18147 Treatment through Multiple Lines Phase III SWOG SO518 Phase III AVAglio # of patients N=810 N=284* N=920 Design 1 st -line treatment with chemotherapy* plus Avastin Once patients progress, they are randomised to: ARM A: Chemotherapy* alone ARM B: Chemotherapy* + Avastin * Physician s choice ARM A: Depot octreotide plus interferon alpha ARM B: Depot octreotide plus Avastin ARM A: Concurrent radiation and temozolomide plus placebo; followed by maintenance temozolomide plus placebo for 6 cycles; then placebo monotherapy until disease progression ARM B: Concurrent radiation and temozolomide plus Avastin; followed by maintenance temozolomide plus Avastin for 6 cycles; then Avastin (15mg/kg q3 weeks) monotherapy until disease progression Avastin dose 5 mg/kg q2 weeks or 7.5 mg/kg q3 weeks 15 mg/kg q3 weeks 10 mg/kg q2 weeks or 15 mg/kg q3 weeks Primary endpoint Overall survival Progression-free survival Overall survival Progression-free survival Status FPI Q1 2006 Enrolment completed Q2 2010 Expect data Q1 2012 FPI Q1 2008 *Protocol being amended; sample size to increase FPI Q2 2009 75

Avastin Adjuvant clinical development programme Patient population Phase/study Adjuvant lung cancer Phase III ECOG 1505 Phase III ECOG 5103 HER2-negative Adjuvant breast cancer Phase III BEATRICE Triple-negative Phase III BETH HER2-positive # of patients N=1,500 N=4,950 N=2,530 N=3,600 Design ARM A: Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed ARM B: Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed plus Avastin up to 12 months ARM A: Anthracycline plus cyclophosphamide (AC) followed by paclitaxel ARM B: AC plus Avastin followed by paclitaxel plus Avastin ARM C: AC plus Avastin followed by paclitaxel plus Avastin, followed by Avastin up to 12 months ARM A: Anthracycline ± taxane or taxane-based chemo alone ARM B: Anthracycline ± taxane or taxane-based chemo plus Avastin for 1 year Avastin dose 15 mg/kg q3 weeks 15 mg/kg q3 weeks Dosing equivalent to 5 mg/kg/w Primary endpoint COHORT 1: Docetaxel/ carboplatin plus Herceptin ± Avastin COHORT 2: Docetaxel plus Herceptin ± Avastin, followed by 5-Fluorouracil, Epirubicin, Cyclophosphamide For both cohorts, patients receive Herceptin ± Avastin to complete one year of targeted therapy 15 mg/kg q3 weeks Overall survival Disease-free survival Disease-free survival Disease-free survival Status FPI Q3 2007 FPI Q4 2007 Expect to complete enrolment Q1 2011 FPI Q4 2007 Enrolment completed Q4 2009 FPI Q2 2008 Enrolment completed Q4 2010 76

Herceptin The standard of care for HER2+ early and mbc; advancing care for HER2+ advanced gastric cancer Patient population Adjuvant HER2-positive breast cancer Advanced HER2-positive gastric cancer (Adenocarcinoma of the stomach or GEJ) Early-stage HER2-positive breast cancer Phase/study Phase III HERA Phase III ToGA Phase III HANNAH # of patients N=5,102 N=584 N=595 Design Primary endpoint Status ARM A: Herceptin for 12 months ARM B: Herceptin for 24 months ARM C: Observation ARM A: Xeloda or 5-FU 1 and cisplatin ARM B: Xeloda or 5-FU 1 and cisplatin plus Herceptin ARM A: Chemotherapy* concurrent with Herceptin subcutaneous for every three weeks for the first 8 cycles ARM B: Chemotherapy* concurrent with Herceptin intravenous for every three weeks for the first 8 cycles *Chemotherapy = docetaxel then 5-FU, epirubicin, and cyclophosphamide Disease-free survival Overall survival Serum concentration Pathologic complete response Final 2-year versus 1-year analysis expected in 2012; event-driven Received EMA approval Q1 2010 Received FDA approval Q4 2010 FPI Q4 2009 Enrolment completed Q4 2010 Expect data end of 2011 1 Xeloda or 5-fluorouracil at investigator s discretion. GEJ = Gastro-oesophageal Junction 77

MabThera/Rituxan Development programmes Patient population Phase/study Front-line follicular non- Hodgkin s lymphoma Phase III Subcutaneous study Study being conducted ex-us # of patients N=405 Design Primary endpoint ARM A: Intravenous MabThera plus chemotherapy (CHOP or CVP) ARM B: Subcutaneous MabThera plus chemotherapy (CHOP or CVP) Responders will continue on maintenance every 8 weeks over 24 months Pharmacokinetics, safety and efficacy Oncology Maintenance treatment for first-line advanced follicular lymphoma Phase III PRIMA* N=1,217 induction N=1,018 maintenance Physician s choice of three chemotherapies plus MabThera/Rituxan, followed by: ARM A: Maintenance regimen of MabThera/Rituxan for responders every 8 weeks over 24 months ARM B: Observation Progression-free survival Status Expect FPI Q1 2011 EMA approval Q4 2010 FDA approval January 2011 Front-line diffuse large B-cell or follicular non-hodgkin s lymphoma Phase IIIb RATE* Faster infusion study Immunology ANCA-associated vasculitis Phase II/III RAVE* N=450 N=197 Prospective, open-label, single arm study To determine the incidence of Grade 3 or 4 infusion-related toxicities resulting from faster infusion of MabThera/Rituxan FPI Q3 2008 Enrolment completed Q4 2010 Expect data H1 2011 Non-inferiority efficacy and safety study of MabThera/Rituxan and glucocorticoids versus conventional therapy (cyclophosphamide) Induction of complete remission at 6 months, defined as a BVAS/WG of 0 and off glucocorticoid therapy Data presented at ACR 2009 US sbla submission Q4 2010 *In collaboration with Biogen Idec CHOP = Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone; CVP = Cyclophosphamide, Vincristine and Prednisolone. 78

Tarceva New approaches to treating lung cancer Patient population Phase/study # of patients Design Primary endpoint Adjuvant non-small cell lung cancer Phase III RADIANT N=974 (2:1 randomisation) Following surgical resection ± adjuvant chemotherapy: ARM A: Tarceva up to 2 years ARM B: Placebo up to 2 years Disease-free survival EGFR IHC and/or FISH-positive Status Enrolment completed Q3 2010 Expect final results in 2013 First-line metastatic non-small cell lung cancer EGFR mutation-positive* Phase III EURTAC First-Line metastatic non-small cell lung cancer EGFR mutation-positive* Phase III OPTIMAL Study conducted in China N=174 N=165 ARM A: Tarceva ARM B: Chemotherapy (platinum-based doublet) Progression-free survival Study met its primary endpoint Q1 2011 Expect FDA snda submission in 2011 ARM A: Tarceva ARM B: Gemcitabine and carboplatin Progression-free survival Positive data presented at ESMO 2010 *In Q2 2010 we submitted an application to the EMA to extend the label for Tarceva to include patients with first-line mnsclc with EGFR activating mutations. The submission was based on published data. Data from the Phase III OPTIMAL study shared with the EMA. In collaboration with OSI Pharmaceuticals, now part of Astellas group of companies in the US. 79

Actemra/RoActemra Interleukin 6 receptor inhibitor Rheumatoid arthritis programme Patient population Early moderate-to-severe rheumatoid arthritis Rheumatoid arthritis DMARD inadequate responders Moderate-to-severe rheumatoid arthritis Moderate-to-severe rheumatoid arthritis Phase/study Phase III FUNCTION Phase III ADACTA Head-to-head study Phase III SUMMACTA Subcutaneous study Phase III BREVACTA Subcutaneous study # of patients N=1,128 N=300 N=1,200 N=600 Design ARM A: Actemra 8 mg/kg ARM B: Actemra 8 mg/kg plus MTX ARM C: Actemra 4 mg/kg plus MTX ARM D: MTX alone ARM A: Actemra ARM B: Humira Add-on to DMARD therapy Weekly dosing ARM A: Subcutaneous Actemra plus intravenous placebo ARM B: Intravenous Actemra plus subcutaneous placebo Add-on to DMARD therapy Dosing every two weeks ARM A: Subcutaneous Actemra ARM B: Subcutaneous placebo Primary endpoint DAS28 remission at 24 weeks DAS28 at 24 weeks ACR 20 at week 24 ACR 20 at week 24 Status FPI Q4 2009 FPI Q2 2010 Expect data late 2011 FPI Q3 2010 Expect data 2012 Expect FPI Q1 2011 In collaboration with Chugai MTX = Methotrexate; DMARD = Disease-Modifying Anti-Rheumatic Drugs. Humira (adalimumab) is a registered trademark of Abbott Laboratories. 80

Actemra/RoActemra Interleukin 6 receptor inhibitor Additional phase III programmes Patient population Systemic juvenile idiopathic arthritis (sjia) Ankylosing spondylitis NSAID failures and TNF-naive Ankylosing spondylitis TNF inadequate responders Phase/study Phase III TENDER Phase III BUILDER 1 Phase III BUILDER 2 # of patients N=108 N=502 N=250 Design Primary endpoint ARM A: Actemra 8 mg/kg and 12 mg/kg every 2 weeks for 12 weeks (dosed by body weight) ARM B: Placebo for 12 weeks Reduction in signs and symptoms plus absence of fever Status FDA and EMA submissions Q4 2010 FDA and EMA granted accelerated review PART 1: ARM A: Actemra 8 mg/kg for 12 weeks ARM B: Placebo for 12 weeks PART 2: ARM C: Actemra 8 mg/kg for 24 weeks ARM D: Actemra 4 mg/kg for 24 weeks ARM E: Placebo for 24 weeks ARM A: Actemra 8 mg/kg ARM B: Actemra 4 mg/kg ARM C: Placebo ASAS20 at week 12 ASAS20 at week 12 FPI Q3 2010 FPI Q4 2010 In collaboration with Chugai EULAR = European League Against Rheumatism; ACR = American College of Rheumatology; TNF = Tumor Necrosis Factor; ASAS = Ankylosing Spondylitis Assessment Score; NSAID = Non-Steroidal Anti-Inflammatory Drugs. 81